163 related articles for article (PubMed ID: 18793033)
41. [ACE-inhibitor effects on the stabilization of coronary heart disease. EUROPA study].
Böhm M
Internist (Berl); 2004 Oct; 45(10):1196-8. PubMed ID: 15372169
[No Abstract] [Full Text] [Related]
42. The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland.
Orlewska E
Value Health; 2002; 5(5):405-21. PubMed ID: 12201858
[TBL] [Abstract][Full Text] [Related]
43. Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study).
Rodriguez-Granillo GA; Vos J; Bruining N; Garcia-Garcia HM; de Winter S; Ligthart JM; Deckers JW; Bertrand M; Simoons ML; Ferrari R; Fox KM; Remme W; De Feyter PJ;
Am J Cardiol; 2007 Jul; 100(2):159-63. PubMed ID: 17631061
[TBL] [Abstract][Full Text] [Related]
44. Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?
Remme WJ; Deckers JW; Fox KM; Ferrari R; Bertrand M; Simoons ML;
Cardiovasc Drugs Ther; 2009 Apr; 23(2):161-70. PubMed ID: 18931896
[TBL] [Abstract][Full Text] [Related]
45. EUROPA: clinical benefits, clinical promise.
Cardiovasc J S Afr; 2004; 15(3):147. PubMed ID: 15356915
[No Abstract] [Full Text] [Related]
46. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
Ferrari R
Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
[TBL] [Abstract][Full Text] [Related]
47. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk.
Deckers JW; Goedhart DM; Boersma E; Briggs A; Bertrand M; Ferrari R; Remme WJ; Fox K; Simoons ML
Eur Heart J; 2006 Apr; 27(7):796-801. PubMed ID: 16497685
[TBL] [Abstract][Full Text] [Related]
48. An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomised placebo-controlled trial (AARDVARK).
Kiru G; Bicknell C; Falaschetti E; Powell J; Poulter N
Health Technol Assess; 2016 Jul; 20(59):1-180. PubMed ID: 27488944
[TBL] [Abstract][Full Text] [Related]
49. VALIANT and EUROPA.
Liebson PR
Prev Cardiol; 2004; 7(1):42-4. PubMed ID: 15010627
[No Abstract] [Full Text] [Related]
50. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
Brugts JJ; Ninomiya T; Boersma E; Remme WJ; Bertrand M; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML
Eur Heart J; 2009 Jun; 30(11):1385-94. PubMed ID: 19346520
[TBL] [Abstract][Full Text] [Related]
51. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy.
Brown RE; Henderson RA; Koster D; Hutton J; Simoons ML
Eur Heart J; 2002 Jan; 23(1):50-8. PubMed ID: 11741362
[TBL] [Abstract][Full Text] [Related]
52. Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
Boos CJ
Med Sci Monit; 2004 Dec; 10(12):SR23-8. PubMed ID: 15567997
[TBL] [Abstract][Full Text] [Related]
53. A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction.
Lamotte M; Annemans L; Kawalec P; Zoellner Y
Pharmacoeconomics; 2006; 24(8):783-95. PubMed ID: 16898848
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective.
Orlewska E; Budaj A; Tereszkowski-Kaminski D
Pharmacoeconomics; 2003; 21(10):737-48. PubMed ID: 12828495
[TBL] [Abstract][Full Text] [Related]
55. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK.
Scuffham PA; Chaplin S
Pharmacoeconomics; 2004; 22(8):525-35. PubMed ID: 15217308
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
[TBL] [Abstract][Full Text] [Related]
57. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
Ferrari R; Pasanisi G; Notarstefano P; Campo G; Gardini E; Ceconi C
Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
[TBL] [Abstract][Full Text] [Related]
58. Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.
Curran MP; McCormack PL; Simpson D
Drugs; 2006; 66(2):235-55. PubMed ID: 16451098
[TBL] [Abstract][Full Text] [Related]
59. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
Rapezzi C; Ciliberti P; Graziosi M; Riva L
Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
[TBL] [Abstract][Full Text] [Related]
60. [Scientific value of the EUROPA Study: mechanisms of beneficial effect of perindopril in atherosclerosis].
Karpov IuA
Kardiologiia; 2005; 45(2):86-9. PubMed ID: 15798719
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
